Chronic Constipation in a Patient Taking Multiple Medications: A Clinical Case Challenge
Release Date: November-15-11
Credit Expiration Date: November-15-12
.
Primary and long-term care physicians, pharmacists, physician assistants, and other health care professionals involved in the care of older adults.
0.5 Contact Hour (0.05 CEU)
0.5 Credit Hour
Clinical Case Challenge (Online)
Chronic constipation, particularly in older adults, can dramatically impact quality of life and lead to serious medical problems. The estimated prevalence of chronic constipation in the U.S. is between 2% and 27%, but this rate increases to 40% among people over 65 years of age. Older adults are at particular risk due to additional chronic disease burdens, polypharmacy, immobility, and/or functional limitations.
Effective management of chronic constipation requires a combination of provider and patient education, lifestyle and/or pharmacologic modifications, and the judicious use of pharmacologic and nonpharmacologic therapies. This clinical case challenge will review approaches to treatment and outline considerations for tailoring care for patients taking multiple medications and medication-induced constipation.
Louis Kuritzky, MD
Family Physician
Clinical Assistant Professor
Dept. of Community Health and Family Medicine
University of Florida
Gainesville, FL
All faculty and staff involved in the planning or presentation of continuing education activities sponsored/provided by the American Society of Consultant Pharmacists (ASCP), and AKH are required to disclose to the audience any real or apparent commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity.
Faculty:
Dr. Kuritzky discloses that he is a consultant and on the speaker's bureau for Takeda.
Additional planning committee members, Medical Communications Media, ASCP, AKH staff have the following to disclose.
ASCP:
Ms. Dechevalier has no relevant financial conflicts to disclose.
Dr. Gerber has no relevant financial conflicts to disclose.
AKH:
Dr. Holman and AKH staff have no relevant financial conflicts to disclose.
MCM:
Ms. Hines has no relevant financial conflicts to disclose.
Dr. Thier has no relevant financial conflicts to disclose.
Dr. Paczolt has no relevant financial conflicts to disclose.
Pharmacy Continuing Education:
The American Society of Consultant Pharmacists (ASCP) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This knowledge-based activity, ACPE Universal Activity #0203-9999-11-161-H01-P, has been assigned 0.5 Contact Hour (0.05 CEU).
Physician Continuing Medical Education: This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of AKH Inc. and Medical Communications Media, Inc. AKH Inc. is accredited by the ACCME to provide continuing medical education for physicians.
AKH Inc. designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit TM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Supported by an education grant from Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals North America, Inc.
© 2011, Medical Communications Media, Inc. All rights reserved. None of the contents may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, ASCP, AKH Inc, Sucampo Pharmaceuticals, Inc., or Takeda Pharmaceuticals North America, Inc. Any medications, diagnostic procedures, or treatments discussed by the faculty should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.